This study investigated the effect of pretreatment with topical diclofenac 0.1 % on the changes in intraocular pressure (lOP) associated with use of an external ocular compression device. The lOP reduction in eyes receiving pretreatment was significantly greater than in controls after 40 minutes of compression, and the recovery in lOP after removal of the compression device was significantly reduced. We conclude that the lOP rise after such com pression is largely prostaglandin mediated, and suggest that use of ocular compression devices is associated with marked intraocular prostaglandin release.
The use of external ocular compression devices to reduce the intraocular pressure (lOP) prior to cataract surgery is well established. Following removal of the device, there is a rapid rebound recovery in lOP to baseline levels, and animal models have identified that prostaglandins are mediators for this lOP increase. This study aimed to inves tigate the effect of pretreatment with topical diclofenac sodium 0.1 % (Voltarol Ophtha, ClBA Vision Ophthal mics, UK) in human volunteers receiving external ocular compression, to establish whether the lOP change was significantly altered by the use of this topical non-steroidal anti-inflammatory drug.
METHOD
Thirty volunteers from the ophthalmology department, staff and patients, were used in this ethically approved study. Subjects were randomised to receive either ocular compression alone, or ocular compression following pre treatment with topical diclofenac 0.1 %. The eye to be tested was selected at random. Subjects with a history of previous ophthalmic surgery, glaucoma, uveitis, systemic vascular disease, or who were receiving any systemic anti inflammatory drug, were excluded from the study. Sub jects in the study group received pretreatment to the test eye of one drop of topical diclofenac 0.1 % every 15 min- Table I . The mean age of the subjects in the study was 41.7 years, with a mean starting lOP of 18.35 mmHg. Seventeen right eyes and 13 left eyes were tested in the study. The mean age is below that of many patients undergoing cataract surgery, but the age range of our subjects was from 19 to 82 years, and we detected no obvious difference in the response across the entire age range studied. All subjects underwent a rapid and signifi cant fall in lOP following external compression using the MacIntyre mercury weight. The test eyes demonstrated a 
RESULTS

Results are shown in
Following removal of the compression device, both groups initially demonstrated a brisk rise in lOP over the first 5 minutes, with an increase in lOP of 2.30 mmHg in the test eyes and 2.36 mmHg in the control eyes -a rate of recovery of approximately 0.46 mmHg/min in each group. After this rapid initial rise, the lOP in the control group continued to recover at a brisk rate, with no signifi cant difference from the starting lOP detected 20 minutes after removal of the compression device -an average rate of 0.35 mmHg/min over this period. The test eyes showed a marked reduction in the rate of recovery of lOP after the first 5 minutes (Fig. 1) , with the rate of increase in lOP falling to 0.19 mmHg/min, and an average rate of recov ery of only 0.23 mmHg/min over a comparable 20 minute period. The mean reduction in lOP from starting levels 10 minutes after removal of the compression device was 6.20 mmHg in the test eyes compared with 4.47 mmHg in the control eyes (p = 0.009), and 5.67 mmHg compared with 1.30 mmHg in the controls at 20 minutes (p<O.OOI). At the end of the study period the control group lOP was mildly elevated from baseline levels with an lOP increase of 0.20 mmHg, but the test eyes still maintained a signifi cant reduction in lOP of 3.30 mmHg (p<O.OOl).
DISCUSSION
External ocular compression devices are extensively used to reduce the lOP prior to cataract surgery, particularly in association with peribulbar and retrobulbar anaesthesia. The reduction in lOP of 8.23 mmHg found in our control group after 40 minutes of compression with the MacIntyre weight compares well with other reports on the use of similar devices, and with levels achieved with general anaesthesia. 2 . 3 The reduction in lOP in the study group, which had received pretreatment with topical diclofenac, was significantly greater than that in the control eyes after 40 minutes of compression, with a mean reduction of 10.23 mmHg (p = 0.037).
Immediately after removing the compression device, all the eyes in the study showed a similar sharp rise in lOP over the first 5 minutes, probably caused by a rebound increase in ocular blood flow as has been previously described following ocular compression. 4 After this rapid initial rise in both groups, the lOP recovery remained brisk in the control eyes, with no significant difference from starting lOP detected after 20 minutes. The mean rate of recovery of IOP in the control group was 0.35 mmHg/min over this period, a level comparable with results from earlier studies of lOP recovery after ocular compression. s . 6 The mechanism for this acute rise in lOP is not clear, but a similar rise is seen in animal eyes following both external ocular compression and ocular injury, and prostaglandins have been implicated as mediators of this response. 7
Aqueous sampling in animal eyes has demonstrated a significant increase in intraocular prostaglandin levels after ocular compression, and these have been identified as prostaglandins E2 and F 2 c/ Experiments administering direct intracameral injections of these agents have repli cated this lOP rise in test eyes, confirming that prosta glandins are mediators of this response in animals. 9 Intraocular micropipette sampling in rabbits has shown the site of action of the prostaglandins to be chiefly on the tight junction of the non-pigmented epithelium of the cili ary body, where they induce a focal breakdown of the blood-aqueous barrier. lo Mathematical modelling sug gests that the change in osmotic forces caused by the resulting increase in aqueous protein levels, together with ciliary vessel vasodilatation induced by the prosta glandins, will cause the acute rise in lOP that is seen clinically.
II
The prostaglandins involved in this response are pro duced by the action of local intraocular prostaglandin synthesising enzyme systems, which are distributed widely throughout the iris stroma. 12 Inhibition of these enzymes would be predicted to block the lOP response, and animal experiments have confirmed this hypothesis, with reports of cases receiving pretreatment with intraperitoneal indomethacin or systemic aspirin showing a significant reduction in the lOP rise after ocular compression. 13 . 14 The test group in our study received pretreatment with topical diclofenac 0.1 %, a potent inhibitor of prosta glandin synthesis that acts largely through inhibition of the cyclo-oxygenase pathway.
I S The lOP reduction in the test group was found to be significantly greater after 40 minutes of compression with the MacIntyre mercury bag, but more significantly the test group clearly demonstrated a marked delay in the rate of lOP recovery after the com pression device was removed. After the brisk initial rise in lOP seen in both groups immediately following removal of the compression device, the rate of lOP recovery in the test group dropped to 0.19 mmHg/min, with an average rate of recovery of 0.23 mmHg/min over the total recov ery period studied. At 30 minutes after removal of the Macintyre weight, the mean lOP reduction in the test group remained 3.3 mmHg below baseline, compared with a mild elevation of 0.2 mmHg above baseline in the control group (p<0.001). These results suggest that the lOP rise seen after external ocular compression in humans is partly prostaglandin mediated, and that the use of top ical diclofenac 0.1 % is effective in blunting this response.
The recovery of IOP was not totally abolished in our test group, and this finding again concurs with the results from animal studies suggesting that other, as yet undetermined, mediators are also involved in this response. It is clear, however, that pretreatment with topical diclofenac 0.1 % has a beneficial effect when used in conjunction with external ocular compression both in achieving, and in maintaining, an optimal lOP reduction prior to surgery. Prostaglandins are also recognised as potent mediators of other intraocular responses such as reactive aqueous changes, leukotaxis and pupillary miosis, 16 and the impli cation that use of an external ocular compression device results in a significant increase in intraocular prosta glandin levels makes a further case for specifically blocking this response with topical non-steroidal anti inflammatory agents prior to surgery.
